IDEAYA BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.94 USD | +3.42% |
|
+7.57% | +12.25% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 151.5 | 406.8 | 909.9 | 874.2 | 2,293 | 2,986 | - | - |
| Enterprise Value (EV) 1 | 151.5 | 406.8 | 663.1 | 501.1 | 1,661 | 2,368 | 2,473 | 2,712 |
| P/E ratio | -2.23 x | -10 x | -16.8 x | -12.8 x | -18.2 x | -18 x | -23.5 x | -17.9 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 20.8 x | 32.6 x | 17.2 x | 98.1 x | 156 x | 30.6 x | 34.2 x |
| EV / Revenue | - | 20.8 x | 23.7 x | 9.84 x | 71 x | 124 x | 25.3 x | 31.1 x |
| EV / EBITDA | - | - | -13.7 x | -8.3 x | -12.6 x | -14.5 x | 38.9 x | -15.9 x |
| EV / FCF | -3.84 x | 7.4 x | -11.4 x | -5.53 x | -14.1 x | -16 x | -13.6 x | -13.1 x |
| FCF Yield | -26% | 13.5% | -8.81% | -18.1% | -7.08% | -6.25% | -7.33% | -7.63% |
| Price to Book | 0.93 x | 1.75 x | 3.02 x | 2.15 x | 3.29 x | 6.66 x | 7.88 x | - |
| Nbr of stocks (in thousands) | 20,200 | 29,055 | 38,490 | 48,114 | 64,459 | 74,765 | - | - |
| Reference price 2 | 7.500 | 14.00 | 23.64 | 18.17 | 35.58 | 39.94 | 39.94 | 39.94 |
| Announcement Date | 3/24/20 | 3/23/21 | 3/15/22 | 3/7/23 | 2/20/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 19.54 | 27.94 | 50.93 | 23.38 | 19.11 | 97.66 | 87.23 |
| EBITDA 1 | - | - | -48.54 | -60.4 | -132 | -162.8 | 63.51 | -170.6 |
| EBIT 1 | -44.27 | -35.34 | -50.27 | -62.5 | -134.4 | -174.9 | -130.3 | -178.9 |
| Operating Margin | - | -180.9% | -179.91% | -122.72% | -574.85% | -915.39% | -133.4% | -205.05% |
| Earnings before Tax (EBT) 1 | -41.98 | -34.5 | -49.76 | -58.66 | -113 | -163.1 | -104.3 | -169.3 |
| Net income 1 | -41.98 | -34.5 | -49.76 | -58.66 | -113 | -165.3 | -125.8 | -178 |
| Net margin | - | -176.55% | -178.1% | -115.17% | -483.05% | -864.95% | -128.85% | -204.05% |
| EPS 2 | -3.360 | -1.400 | -1.410 | -1.420 | -1.960 | -2.213 | -1.697 | -2.232 |
| Free Cash Flow 1 | -39.42 | 54.97 | -58.42 | -90.62 | -117.6 | -148 | -181.3 | -207 |
| FCF margin | - | 281.35% | -209.09% | -177.92% | -502.85% | -774.54% | -185.69% | -237.3% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/24/20 | 3/23/21 | 3/15/22 | 3/7/23 | 2/20/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 8.976 | 2.963 | 11.36 | 5.851 | 29.7 | 4.022 | 7.88 | 3.544 | 8.038 | 3.923 | 4.89 | 4.813 | 5.459 | 5.311 |
| EBITDA 1 | -11.26 | -17.92 | -13.76 | -21.99 | 1.229 | -25.89 | -25.69 | - | - | - | -38.59 | -40.63 | -42.88 | -45.33 |
| EBIT 1 | -11.71 | -18.37 | -14.22 | -22.5 | 0.66 | -26.44 | -26.28 | -32.71 | -33.53 | -41.92 | -41.52 | -42.98 | -43.95 | -46.59 |
| Operating Margin | -130.49% | -619.95% | -125.19% | -384.53% | 2.22% | -657.48% | -333.49% | -922.94% | -417.09% | -1,068.44% | -849.08% | -892.91% | -805.18% | -877.28% |
| Earnings before Tax (EBT) 1 | -11.58 | -18.21 | -14.01 | -22.06 | 1.615 | -24.2 | -23.64 | -27.93 | -27.44 | -33.96 | -39.16 | -40.13 | -40.67 | -43.24 |
| Net income 1 | -11.58 | -18.21 | -14.01 | -22.06 | 1.615 | -24.2 | -23.64 | -27.93 | -27.44 | -33.96 | -39.26 | -40.36 | -41.37 | -44.41 |
| Net margin | -129.03% | -614.65% | -123.36% | -376.96% | 5.44% | -601.72% | -300% | -787.98% | -341.38% | -865.54% | -802.7% | -838.48% | -757.9% | -836.32% |
| EPS 2 | -0.3100 | -0.4700 | -0.3600 | -0.5700 | 0.0400 | -0.5000 | -0.4900 | -0.5000 | -0.4600 | -0.5200 | -0.5211 | -0.5344 | -0.5444 | -0.5844 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/15/21 | 3/15/22 | 5/10/22 | 8/15/22 | 11/8/22 | 3/7/23 | 5/9/23 | 8/10/23 | 11/7/23 | 2/20/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 247 | 373 | 633 | 618 | 514 | 274 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -39.4 | 55 | -58.4 | -90.6 | -118 | -148 | -181 | -207 |
| ROE (net income / shareholders' equity) | -163% | -23.1% | -19.9% | -18% | -23.3% | -33% | -32.5% | -30.1% |
| ROA (Net income/ Total Assets) | -40.1% | -16.8% | -14.6% | -15.2% | -21.8% | -38.6% | -36.3% | - |
| Assets 1 | 104.8 | 205.6 | 339.8 | 384.7 | 518.6 | 428.2 | 346.6 | - |
| Book Value Per Share 2 | 8.030 | 8.020 | 7.820 | 8.430 | 10.80 | 6.000 | 5.070 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 1.35 | 0.49 | 2.64 | 3.44 | 2.37 | 2.4 | 3.33 | 4 |
| Capex / Sales | - | 2.52% | 9.46% | 6.76% | 10.13% | 12.56% | 3.41% | 4.59% |
| Announcement Date | 3/24/20 | 3/23/21 | 3/15/22 | 3/7/23 | 2/20/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
39.94
USD
Average target price
53.5
USD
Spread / Average Target
+33.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.25% | 2.99B | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- IDYA Stock
- Financials IDEAYA Biosciences, Inc.
